NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NEXI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NEXI-001 overview
NEXI-001 (AIM-ACT) is under development for the treatment of acute myelogenous leukemia, myeloid dysplastic syndrome (MDS). It was administered through the intravenous route. The therapeutic candidate comprises allogenic CD8+T-cells that act by targeting WT1, Prame and Cyclin A1 antigens. The drug candidate was developed based on artificial IMmune (AIM) technology. It was also under development for HPV-associated cancers including head and neck squamous cell carcinoma.
NexImmune overview
NexImmune is a clinical-stage biotechnology company that specializes in the development of immunotherapies using its proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform. The company’s pipeline products include NEXI-001 an allogeneic cell therapy that targets acute myeloid leukemia (AML) and myelodysplastic syndromes; NEXI-002 is an autologous cell therapy for multiple myeloma; NEXI-003 treats HPV-associated malignancies; NEXI-004 treats EBV associated diseases; and NEXI-005 for solid tumor. Its other injectable modality-based products include NEXI-200 Series, NEXI-300 and NEXI-100 treat autoimmune diseases, infectious diseases and heme and solid tumors. NexImmune is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of NEXI-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.